CEE Legal Matters
In-depth coverage of the news and newsmakers that shape Europe's emerging markets
On March 24, 2021, CEE Legal Matters reported that Djingov, Gouginski, Kyutchukov & Velichkov had advised the founders of tech start-up MYX AD on EUR 350,000 invested into the company by a group led by New Vision 3 Fund KD. CEE In-House Matters spoke with Yordan Zarev, Partner at New Vision 3 Fund, to learn more about the matter.
Vladislav Nikolov, General Counsel at EnduroSat in Sofia, Bulgaria, explains why creative problem-solving, critical thinking, and communication skills are necessary for GCs in today’s world.
Anton Petrov, Head International Legal Affairs and Deputy Director Legal at First Investment Bank in Sofia, Bulgaria, shares tips and tricks for managing relationships with external counsel.
According to Kameliya Naydenova, Legal Counsel South Central Europe at Mondelez International in Bulgaria, the market has somewhat recovered from the blast wave of the COVID-19 crisis. Yet, many industries still need to overcome the change in demand and consumer habits, as well as certain difficulties brought on by the pandemic.
On November 18, 2020, CEE Legal Matters reported that Gugushev & Partners had helped Fr. Lurssen Werft GmbH & Co KG, part of Northern Germany's Lurssen shipyard group, win a public tender for the supply of two multipurpose modular patrol vessels to the Bulgarian Navy. CEEIHM spoke with Dirk Malgowski, Managing Director at Fr. Lurssen Werft, to learn more about the matter.
On January 18, 2021, CEE Legal Matters reported that DGKV had represented the Mezzanine Partners consortium in a public procurement dispute with the Bulgarian Fund of Funds. CEEIHM spoke with Evgeny Angelov, Managing Partner at Silverline Capital, to learn more.
Having worked in the banking sector during the global financial crisis that started in 2008, Iliana Byanova, Chief Legal, Risk and Compliance Officer at Sopharma Trading, talks about the similarities between the effects of that crisis on the Banking sector and those of the COVID-19 pandemic on the pharmaceutical sector.
